Skip to content

JBIO JBIO Free cash flow

Free cash flow at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.29B+66.4%
Climb Global Solutions, Inc. logo
Climb Global Solutions, Inc.CLMB
$16.35M+112%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$106.52M-95.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K

Valuation

See full
Market cap$1.33B+316%
Enterprise value$1.27B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

The official record: JBIO’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's free cash flow?
JBIO (JBIO) reported free cash flow of -$33.65M in Q4 2025.
What is the long-term trend for JBIO's free cash flow?
Over 3 years (2021 to 2025), JBIO's free cash flow has grown at a 51.0% compound annual growth rate (CAGR), from -$27.58M to -$94.89M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.